This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01225/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/company/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01225/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01225/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/patent/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB01225/identifier/drugbank/
n21http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01225
rdf:type
n3:Drug
n3:description
Enoxaparin is a low molecular weight heparin. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin's inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
n3:dosage
n4:271B5A1F-363D-11E5-9242-09173F13E4C5 n4:271B5A19-363D-11E5-9242-09173F13E4C5 n4:271B5A1A-363D-11E5-9242-09173F13E4C5 n4:271B5A1B-363D-11E5-9242-09173F13E4C5 n4:271B5A1C-363D-11E5-9242-09173F13E4C5 n4:271B5A20-363D-11E5-9242-09173F13E4C5 n4:271B5A1D-363D-11E5-9242-09173F13E4C5 n4:271B5A1E-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
4.5 hours
n3:indication
For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
owl:sameAs
n8:DB01225 n11:DB01225
dcterms:title
Enoxaparin
adms:identifier
n19:Enoxaparin n22:PA449463 n24:0075-2915-01 n25:DB01225
n3:mechanismOfAction
The mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa.
n3:packager
n12:271B5A09-363D-11E5-9242-09173F13E4C5 n12:271B5A0A-363D-11E5-9242-09173F13E4C5 n12:271B5A0D-363D-11E5-9242-09173F13E4C5 n12:271B5A0B-363D-11E5-9242-09173F13E4C5 n12:271B5A0C-363D-11E5-9242-09173F13E4C5
n3:patent
n6:2045433 n6:5389618
n3:routeOfElimination
Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.
n3:synonym
Low Molecular Weight Heparin LMWH
n3:toxicity
Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.
n3:volumeOfDistribution
* 4.3 L
n9:hasAHFSCode
n10:20-12-04-16 n10:92-00-00
n3:foodInteraction
Avoid danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark
n3:proteinBinding
80% bound-albumin
n3:synthesisReference
Jorgen I. Nielsen, "Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin." U.S. Patent US5106734, issued May, 1981.
n14:hasConcept
n15:M0027160
foaf:page
n17:lovenox.htm n20:enoxaparin.html
n3:InChI
n13:271B5A25-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n13:271B5A24-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B5A21-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n13:271B5A22-363D-11E5-9242-09173F13E4C5
n3:SMILES
n13:271B5A23-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n13:271B5A27-363D-11E5-9242-09173F13E4C5
n3:logP
n13:271B5A28-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n21:B01AB05
n3:InChIKey
n13:271B5A26-363D-11E5-9242-09173F13E4C5
n3:absorption
Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
9005-49-6
n3:category
n3:containedIn
n5:271B5A17-363D-11E5-9242-09173F13E4C5 n5:271B5A10-363D-11E5-9242-09173F13E4C5 n5:271B5A11-363D-11E5-9242-09173F13E4C5 n5:271B5A0E-363D-11E5-9242-09173F13E4C5 n5:271B5A0F-363D-11E5-9242-09173F13E4C5 n5:271B5A14-363D-11E5-9242-09173F13E4C5 n5:271B5A15-363D-11E5-9242-09173F13E4C5 n5:271B5A12-363D-11E5-9242-09173F13E4C5 n5:271B5A13-363D-11E5-9242-09173F13E4C5 n5:271B5A18-363D-11E5-9242-09173F13E4C5 n5:271B5A16-363D-11E5-9242-09173F13E4C5